<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281697</url>
  </required_header>
  <id_info>
    <org_study_id>AVF3693g</org_study_id>
    <nct_id>NCT00281697</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Treated Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This phase III, multicenter, randomized, placebo-controlled, blinded trial is designed to
      evaluate the efficacy and safety of bevacizumab when combined with standard chemotherapy
      compared with chemotherapy alone in subjects with previously treated metastatic breast
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For all Outcome Measures except Overall Survival and One-year Survival, the Time Frame was
      from Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years 2
      months). For the Outcome Measures Overall Survival and One-year Survival, the Time Frame was
      from Baseline to the end of the study (up to 6 years, 7 months).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months)</time_frame>
    <description>PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival Within Individual Standard Chemotherapy Cohorts (Taxanes, Gemcitabine, Capecitabine, and Vinorelbine)</measure>
    <time_frame>Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months)</time_frame>
    <description>Progression-free survival was defined as the time from randomization to first documented disease progression as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first. Results are reported for each of the 4 standard chemotherapy cohorts used in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Baseline to the end of the study (up to 6 years, 7 months)</time_frame>
    <description>Overall survival was defined as the time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year Survival</measure>
    <time_frame>Baseline to the end of the study (up to 6 years, 7 months)</time_frame>
    <description>Percentage of patients who survived 1 year in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response</measure>
    <time_frame>Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months)</time_frame>
    <description>A patient had an objective response if they had a complete response or a partial response determined on two consecutive occasions ≥ 4 weeks apart as determined by the investigator using RECIST. For target lesions, a complete response was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. For non-target lesions, a complete response was defined as the disappearance of all non-target lesions; a partial response was defined as the persistence of 1 or more non-target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response</measure>
    <time_frame>Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months)</time_frame>
    <description>Duration of objective response was defined as the time from the initial response to documented disease progression or death from any cause, whichever occurred first. Duration of objective response was only analyzed in patients who achieved an objective response.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">684</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Standard chemotherapy + bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard chemotherapy + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>The dose of bevacizumab was based on a patient's weight at baseline and remained the same throughout the study.</description>
    <arm_group_label>Standard chemotherapy + bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Standard chemotherapy + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard chemotherapy</intervention_name>
    <description>Patients received one of the following four standard chemotherapies for metastatic breast cancer.
Taxane - Paclitaxel (Taxol) 90 mg/m^2 IV every week for 3 weeks followed by 1 week of rest; paclitaxel (Taxol) 175 mg/m^2 IV every 3 weeks, or paclitaxel protein-bound particles (Abraxane) 260 mg/m^2 IV every 3 weeks; or docetaxel (Taxotere) 75-100 mg/m^2 IV every 3 weeks.
Gemcitabine (Gemzar) 1250 mg/m^2 IV on Days 1 and 8 of each 3-week cycle.
Vinorelbine (Navelbine) 30 mg/m^2 IV every week of each 3-week cycle.
Capecitabine (Xeloda) 1000 mg/m^2 orally twice daily on Days 1-14 of each 3-week cycle.</description>
    <arm_group_label>Standard chemotherapy + bevacizumab</arm_group_label>
    <arm_group_label>Standard chemotherapy + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form.

          -  ≥ 18 years of age.

          -  Histologically confirmed carcinoma of the breast with measurable or non-measurable
             metastatic disease that has progressed (patients with a history of brain metastasis
             are eligible for study participation [USA only], as long as their brain metastases
             have been treated and they have no evidence of progression or hemorrhage after
             treatment and no ongoing requirement for dexamethasone).

          -  Progression of disease during or following administration of one (non-investigational)
             chemotherapy regimen administered in the first-line setting.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  For women of childbearing potential, use of an effective means of non-hormonal
             contraception.

          -  Life expectancy ≥ 3 months.

          -  Willingness and capacity to comply with study and follow-up procedures.

        Exclusion Criteria:

          -  Prior hormonal therapy only as treatment for metastatic disease without chemotherapy.
             Patients must have received chemotherapy for their metastatic disease in the
             first-line setting. Hormone therapy alone is not allowed.

          -  For subjects who have received prior anthracycline-based therapy, documentation of
             left ventricular ejection fraction &lt; 50% by either multiple gated acquisition (MUGA)
             or echocardiogram (ECHO).

          -  Treatment with more than one prior cytotoxic regimen for metastatic breast cancer
             (MBC).

          -  HER2-positive status (patients who have unknown HER2 status, and for whom
             determination of HER2 status is not possible, are eligible for this study).

          -  Unknown estrogen receptor (ER) and progesterone receptor (PR) status.

          -  Radiation therapy other than for palliation or brain metastasis, biologic therapy, or
             chemotherapy for MBC within 21 days prior to Day 0 (Day 1 of Cycle 1 of treatment).

          -  Prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF)
             pathway-targeted therapy.

          -  Untreated brain metastasis.

          -  Inadequately controlled hypertension.

          -  Unstable angina.

          -  New York Heart Association Grade II or greater congestive heart failure (CHF).

          -  History of myocardial infarction within 6 months prior to Day 0 (the day of the first
             bevacizumab/placebo infusion).

          -  History of stroke or transient ischemic attack within 6 months prior to Day 0.

          -  Clinically significant peripheral vascular disease.

          -  Evidence of bleeding diathesis or coagulopathy.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 0; anticipation of need for major elective surgical procedure during the
             study.

          -  Minor surgical procedures, fine-needle aspirations, or core biopsies within 7 days
             prior to Day 0.

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to Day 0.

          -  Serious, non-healing wound, ulcer, or bone fracture.

          -  History of anaphylactic reaction to monoclonal antibody therapy not controlled with
             treatment premedication.

          -  History of other malignancies within 5 years of Day 0, except for tumors with a
             negligible risk for metastasis or death, such as adequately controlled basal cell
             carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.

          -  inadequate organ function.

          -  Pregnancy (positive serum pregnancy test) or lactation.

          -  Any other diseases, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that may affect the
             interpretation of the results or renders the subject at high risk from treatment
             complications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leo Faoro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Former Serbia and Montenegro</country>
    <country>France</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2006</study_first_submitted>
  <study_first_submitted_qc>January 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2006</study_first_posted>
  <results_first_submitted>August 23, 2012</results_first_submitted>
  <results_first_submitted_qc>August 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 24, 2012</results_first_posted>
  <last_update_submitted>July 5, 2013</last_update_submitted>
  <last_update_submitted_qc>July 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ribbon 2</keyword>
  <keyword>Avastin</keyword>
  <keyword>MBC</keyword>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Chemotherapy + Bevacizumab</title>
          <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
        </group>
        <group group_id="P2">
          <title>Standard Chemotherapy + Placebo</title>
          <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="459"/>
                <participants group_id="P2" count="225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="401"/>
                <participants group_id="P2" count="197"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>&gt; 60 days since last dose of study drug</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="279"/>
                <participants group_id="P2" count="149"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician's decision to withdraw</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject/guardian's decision to withdraw</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive study drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Chemotherapy + Bevacizumab</title>
          <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
        </group>
        <group group_id="B2">
          <title>Standard Chemotherapy + Placebo</title>
          <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="459"/>
            <count group_id="B2" value="225"/>
            <count group_id="B3" value="684"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.6" spread="11.0"/>
                    <measurement group_id="B2" value="55.0" spread="11.2"/>
                    <measurement group_id="B3" value="55.4" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="457"/>
                    <measurement group_id="B2" value="225"/>
                    <measurement group_id="B3" value="682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.</description>
        <time_frame>Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months)</time_frame>
        <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Chemotherapy + Bevacizumab</title>
            <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
          </group>
          <group group_id="O2">
            <title>Standard Chemotherapy + Placebo</title>
            <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.</description>
          <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="6.5" upper_limit="7.6"/>
                    <measurement group_id="O2" value="5.1" lower_limit="4.1" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival Within Individual Standard Chemotherapy Cohorts (Taxanes, Gemcitabine, Capecitabine, and Vinorelbine)</title>
        <description>Progression-free survival was defined as the time from randomization to first documented disease progression as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first. Results are reported for each of the 4 standard chemotherapy cohorts used in the study.</description>
        <time_frame>Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months)</time_frame>
        <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Chemotherapy + Bevacizumab</title>
            <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
          </group>
          <group group_id="O2">
            <title>Standard Chemotherapy + Placebo</title>
            <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival Within Individual Standard Chemotherapy Cohorts (Taxanes, Gemcitabine, Capecitabine, and Vinorelbine)</title>
          <description>Progression-free survival was defined as the time from randomization to first documented disease progression as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first. Results are reported for each of the 4 standard chemotherapy cohorts used in the study.</description>
          <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Taxanes, n=201, 103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="7.2" upper_limit="9.3"/>
                    <measurement group_id="O2" value="5.8" lower_limit="4.2" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gemcitabine, n=108, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="5.5" upper_limit="7.1"/>
                    <measurement group_id="O2" value="5.5" lower_limit="2.6" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Capecitabine, n=97, 47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="5.5" upper_limit="8.5"/>
                    <measurement group_id="O2" value="4.1" lower_limit="2.8" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vinorelbine, n=53, 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="3.5" upper_limit="7.5"/>
                    <measurement group_id="O2" value="7.0" lower_limit="2.7" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival was defined as the time from randomization to death from any cause.</description>
        <time_frame>Baseline to the end of the study (up to 6 years, 7 months)</time_frame>
        <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Chemotherapy + Bevacizumab</title>
            <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
          </group>
          <group group_id="O2">
            <title>Standard Chemotherapy + Placebo</title>
            <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival was defined as the time from randomization to death from any cause.</description>
          <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="17.4" upper_limit="20.0"/>
                    <measurement group_id="O2" value="17.8" lower_limit="15.1" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>One-year Survival</title>
        <description>Percentage of patients who survived 1 year in the study.</description>
        <time_frame>Baseline to the end of the study (up to 6 years, 7 months)</time_frame>
        <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Chemotherapy + Bevacizumab</title>
            <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
          </group>
          <group group_id="O2">
            <title>Standard Chemotherapy + Placebo</title>
            <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
          </group>
        </group_list>
        <measure>
          <title>One-year Survival</title>
          <description>Percentage of patients who survived 1 year in the study.</description>
          <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" lower_limit="66.3" upper_limit="74.7"/>
                    <measurement group_id="O2" value="68.6" lower_limit="62.5" upper_limit="74.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response</title>
        <description>A patient had an objective response if they had a complete response or a partial response determined on two consecutive occasions ≥ 4 weeks apart as determined by the investigator using RECIST. For target lesions, a complete response was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. For non-target lesions, a complete response was defined as the disappearance of all non-target lesions; a partial response was defined as the persistence of 1 or more non-target lesions.</description>
        <time_frame>Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months)</time_frame>
        <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment. Only patients who had measurable disease at baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Chemotherapy + Bevacizumab</title>
            <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
          </group>
          <group group_id="O2">
            <title>Standard Chemotherapy + Placebo</title>
            <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response</title>
          <description>A patient had an objective response if they had a complete response or a partial response determined on two consecutive occasions ≥ 4 weeks apart as determined by the investigator using RECIST. For target lesions, a complete response was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. For non-target lesions, a complete response was defined as the disappearance of all non-target lesions; a partial response was defined as the persistence of 1 or more non-target lesions.</description>
          <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment. Only patients who had measurable disease at baseline were included in the analysis.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5" lower_limit="34.4" upper_limit="44.7"/>
                    <measurement group_id="O2" value="29.6" lower_limit="23.0" upper_limit="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Objective Response</title>
        <description>Duration of objective response was defined as the time from the initial response to documented disease progression or death from any cause, whichever occurred first. Duration of objective response was only analyzed in patients who achieved an objective response.</description>
        <time_frame>Baseline to data cut-off for analysis of the primary Outcome Measure (up to 3 years, 2 months)</time_frame>
        <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment. Only patients who had measurable disease at baseline and achieved an objective response were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Chemotherapy + Bevacizumab</title>
            <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
          </group>
          <group group_id="O2">
            <title>Standard Chemotherapy + Placebo</title>
            <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Objective Response</title>
          <description>Duration of objective response was defined as the time from the initial response to documented disease progression or death from any cause, whichever occurred first. Duration of objective response was only analyzed in patients who achieved an objective response.</description>
          <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment. Only patients who had measurable disease at baseline and achieved an objective response were included in the analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="6.2" upper_limit="8.2"/>
                    <measurement group_id="O2" value="7.5" lower_limit="6.6" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from Baseline to the end of the study (up to 6 years, 7 months).</time_frame>
      <desc>Adverse events are reported for safety-evaluable population defined as all randomized patients who received study treatment, defined as at least 1 full or partial dose of bevacizumab, placebo, or standard chemotherapy.</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard Chemotherapy + Bevacizumab</title>
          <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
        </group>
        <group group_id="E2">
          <title>Standard Chemotherapy + Placebo</title>
          <description>Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Periproctitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hepatitis cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Fascitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tumour necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cranial nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Superior vena caval syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="458"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Genentech, Inc.</organization>
      <phone>800 821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

